Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Denali Therapeutics (DNLI) Other Accumulated Expenses (2017 - 2022)

Historic Other Accumulated Expenses for Denali Therapeutics (DNLI) over the last 6 years, with Q4 2022 value amounting to $4.4 million.

  • Denali Therapeutics' Other Accumulated Expenses fell 9174.64% to $4.4 million in Q4 2022 from the same period last year, while for Dec 2022 it was $4.4 million, marking a year-over-year decrease of 9174.64%. This contributed to the annual value of $4.4 million for FY2022, which is 9174.64% down from last year.
  • Per Denali Therapeutics' latest filing, its Other Accumulated Expenses stood at $4.4 million for Q4 2022, which was down 9174.64% from $53.2 million recorded in Q4 2021.
  • Denali Therapeutics' Other Accumulated Expenses' 5-year high stood at $53.2 million during Q4 2021, with a 5-year trough of $47000.0 in Q2 2018.
  • For the 5-year period, Denali Therapeutics' Other Accumulated Expenses averaged around $14.1 million, with its median value being $3.5 million (2019).
  • As far as peak fluctuations go, Denali Therapeutics' Other Accumulated Expenses surged by 3080158.73% in 2018, and later tumbled by 9174.64% in 2022.
  • Denali Therapeutics' Other Accumulated Expenses (Quarter) stood at $19.5 million in 2018, then increased by 23.36% to $24.0 million in 2019, then soared by 96.31% to $47.1 million in 2020, then grew by 12.77% to $53.2 million in 2021, then tumbled by 91.75% to $4.4 million in 2022.
  • Its Other Accumulated Expenses was $4.4 million in Q4 2022, compared to $53.2 million in Q4 2021 and $47.1 million in Q4 2020.